Answer: Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo), have become increasingly popular for obesity treatment (Mehrtash, JAMA Intern Med 2025)
Pero seguiremos atentos.
The short half-life of native GLP-1, typically only 12 min due to rapid degradation, has facilitated the development of structurally modified GLP-1 analogs with longer half-lives, such as liraglutide, exendin-4, and dulaglutide, which exhibit 97%, 53%, and 90% sequence homology, respectively 12
Glutathione, the main active ingredient, is a naturally occurring antioxidant in the body
Semaglutide is a second-generation injectable medication, which will eventually replace the first-generation liraglutide (Saxenda, Victoza)